Rituximab-induced HMGB1 release is associated with inhibition of STAT3 activity in human diffuse large B-cell lymphoma

Oncotarget

Volumn 6, Issue 29, 2015, Pages 27816-27831

  Zhao, Tiansuo ^a   Ren, He ^a   Wang, Xiuchao ^a   Liu, Pengfei ^a   Yan, Fan ^a   Jiang, Wenna ^a   Li, Yang ^a   Li, Jing ^a   Gribben, John G ^b   Jia, Li ^b   Hao, Jihui ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

DLBCL; hMGB1; Immunogenic cell death; Rituximab; STAT3

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; GAMMA INTERFERON; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 10; PREDNISONE; RITUXIMAB; STAT3 PROTEIN; VINCRISTINE; ANTINEOPLASTIC AGENT; HMGB1 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; R-CHOP PROTOCOL; STAT3 PROTEIN, HUMAN;

ARTICLE; CELL MATURATION; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; HUMAN; IMMUNE RESPONSE; IMMUNOPRECIPITATION; LARGE CELL LYMPHOMA; PHAGOCYTOSIS; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; APOPTOSIS; DIFFUSE LARGE B CELL LYMPHOMA; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; METABOLISM; SECRETION (PROCESS); TUMOR CELL CULTURE; TUMOR CELL LINE; WESTERN BLOTTING;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HMGB1 PROTEIN; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; LYMPHOMA, LARGE B-CELL, DIFFUSE; PREDNISONE; RITUXIMAB; STAT3 TRANSCRIPTION FACTOR; TUMOR CELLS, CULTURED; VINCRISTINE;

EID: 84944452484     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4816     Document Type: Article

References (53)

1. Younes A, Thieblemont C, Morschhauser F, Flinn I, Friedberg JW, Amorim S, Hivert B, Westin J, Vermeulen J, Bandyopadhyay N, de Vries R, Balasubramanian S, Hellemans P, et al. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (r-chop) for treatment-naive patients with cd20-positive b-cell non-hodgkin lymphoma: A non-randomised, phase 1b study. Lancet Oncol. 2014; 15:1019-1026.
2. Flinn IW, van der Jagt R, Kahl BS, Wood P, Hawkins TE, Macdonald D, Hertzberg M, Kwan YL, Simpson D, Craig M, Kolibaba K, Issa S, Clementi R, et al. Randomized trial of bendamustine-rituximab or r-chop/r-cvp in first-line treatment of indolent nhl or mcl: The bright study. Blood. 2014; 123:2944-2952.
3. Lim SH, Beers SA, French RR, Johnson PW, Glennie MJ, Cragg MS. Anti-cd20 monoclonal antibodies: Historical and future perspectives. Haematologica. 2010; 95:135-143.
4. Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, Lefort S, Marit G, Macro M, Sebban C, Belhadj K, Bordessoule D, Ferme C, Tilly H. Long-term outcome of patients in the lnh-98.5 trial, the first randomized study comparing rituximab-chop to standard chop chemotherapy in dlbcl patients: A study by the groupe d'etudes des lymphomes de l'adulte. Blood. 2010; 116:2040-2045.
5. Recher C, Coiffier B, Haioun C, Molina TJ, Ferme C, Casasnovas O, Thieblemont C, Bosly A, Laurent G, Morschhauser F, Ghesquieres H, Jardin F, Bologna S, et al. Intensified chemotherapy with acvbp plus rituximab versus standard chop plus rituximab for the treatment of diffuse large b-cell lymphoma (lnh03-2b): An open-label randomised phase 3 trial. Lancet. 2011; 378:1858-1867.
6. Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, Dakhil SR, Woda B, Fisher RI, Peterson BA, Horning SJ. Rituximab-chop versus chop alone or with maintenance rituximab in older patients with diffuse large b-cell lymphoma. J Clin Oncol. 2006; 24:3121-3127.
7. Maloney DG, Grillo-Lopez AJ, Bodkin DJ, White CA, Liles TM, Royston I, Varns C, Rosenberg J, Levy R. Idec-c2b8: Results of a phase i multiple-dose trial in patients with relapsed non-hodgkin's lymphoma. J Clin Oncol. 1997; 15:3266-3274.
8. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, et al. Rituximab chimeric anti-cd20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol. 1998; 16:2825-2833.
9. Weiner GJ. Rituximab: Mechanism of action. Seminars in hematology. 2010; 47:115-123.
10. Ivanov A, Beers SA, Walshe CA, Honeychurch J, Alduaij W, Cox KL, Potter KN, Murray S, Chan CH, Klymenko T, Erenpreisa J, Glennie MJ, Illidge TM, Cragg MS. Monoclonal antibodies directed to cd20 and hla-dr can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. J Clin Invest. 2009; 119:2143-2159.
11. Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanisms of killing by anti-cd20 monoclonal antibodies. Mol Immunol. 2007; 44:3823-3837.
12. Alas S, Bonavida B. Rituximab inactivates signal transducer and activation of transcription 3 (stat3) activity in b-non-hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of bcl-2 and sensitization to cytotoxic drugs. Cancer Res. 2001; 61:5137-5144.
13. Patz M, Isaeva P, Forcob N, Muller B, Frenzel LP, Wendtner CM, Klein C, Umana P, Hallek M, Krause G. Comparison of the in vitro effects of the anti-cd20 antibodies rituximab and ga101 on chronic lymphocytic leukaemia cells. Br J Haematol. 2011; 152:295-306.
14. Alduaij W, Ivanov A, Honeychurch J, Cheadle EJ, Potluri S, Lim SH, Shimada K, Chan CH, Tutt A, Beers SA, Glennie MJ, Cragg MS, Illidge TM. Novel type ii anti-cd20 monoclonal antibody (ga101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in b-cell malignancies. Blood. 2011; 117:4519-4529.
15. Abes R, Gelize E, Fridman WH, Teillaud JL. Long-lasting antitumor protection by anti-cd20 antibody through cellular immune response. Blood. 2010; 116:926-934.
16. Hilchey SP, Hyrien O, Mosmann TR, Livingstone AM, Friedberg JW, Young F, Fisher RI, Kelleher RJ Jr, Bankert RB, Bernstein SH. Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific t-cell response in patients with follicular lymphoma: Support for a "vaccinal effect" of rituximab. Blood. 2009; 113:3809-3812.
17. Selenko N, Maidic O, Draxier S, Berer A, Jager U, Knapp W, Stockl J. Cd20 antibody (c2b8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of cd8+ cytotoxic t cells. Leukemia. 2001; 15:1619-1626.
18. Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and damps in cancer therapy. Nat Rev Cancer. 2012; 12:860-875.
19. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T,Casares N, Metivier D, Larochette N, van Endert P, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007; 13:54-61.
20. Inoue H, Tani K. Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments. Cell Death Differ. 2014; 21:39-49.
21. Martins I, Wang Y, Michaud M, Ma Y, Sukkurwala AQ, Shen S, Kepp O, Metivier D, Galluzzi L, Perfettini JL, Zitvogel L, Kroemer G. Molecular mechanisms of atp secretion during immunogenic cell death. Cell Death Differ. 2014; 21:79-91.
22. Yamazaki T, Hannani D, Poirier-Colame V, Ladoire S, Locher C, Sistigu A, Prada N, Adjemian S, Catani JP, Freudenberg M, Galanos C, Andre F, Kroemer G, Zitvogel L. Defective immunogenic cell death of hmgb 1-deficient tumors: Compensatory therapy with tlr4 agonists. Cell Death Differ. 2014; 21:69-78.
23. Andersson U, Tracey KJ. Hmgb1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol. 2011; 29:139-162.
24. Bianchi ME, Manfredi AA. High-mobility group box 1 (hmgb1) protein at the crossroads between innate and adaptive immunity. Immunol Rev. 2007; 220:35-46.
25. Beyer C, Stearns NA, Giessl A, Distler JH, Schett G, Pisetsky DS. The extracellular release of dna and hmgb1 from jurkat t cells during in vitro necrotic cell death. Innate Immun. 2012; 18:727-737.
26. Diener KR, Al-Dasooqi N, Lousberg EL, Hayball JD. The multifunctional alarmin hmgb1 with roles in the pathophysiology of sepsis and cancer. Immunol Cell Biol. 2013; 91:443-450.
27. Apetoh L, Ghiringhelli F, Tesniere A, Criollo A, Ortiz C, Lidereau R, Mariette C, Chaput N, Mira JP, Delaloge S, Andre F, Tursz T, Kroemer G, Zitvogel L. The interaction between hmgb1 and tlr4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev. 2007; 220:47-59.
28. Sims G, Rowe D, Rietdijk S, Herbst R, Coyle A. Hmgb1 and rage in inflammation and cancer. Annu Rev Immunol. 2010; 28:367-388.
29. Cheadle EJ, Sidon L, Dovedi SJ, Melis MH, Alduaij W, Illidge TM, Honeychurch J. The induction of immunogenic cell death by type ii anti-cd20 monoclonal antibodies has mechanistic differences compared with type i rituximab. Br J Haematol. 2013; 162:842-845.
30. Gardella S, Andrei C, Ferrera D, Lotti L, Torrisi M, Bianchi M, Rubartelli A. The nuclear protein hmgb1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep. 2002; 3:995-1001.
31. Agresti A, Bianchi ME. Hmgb proteins and gene expression. Curr Opin Genet Dev. 2003; 13:170-178.
32. Jia L, Clear A, Liu FT, Matthews J, Uddin N, McCarthy A, Hoxha E, Durance C, Iqbal S, Gribben JG. Extracellular hmgb1 promotes differentiation of nurse-like cells in chronic lymphocytic leukemia. Blood. 2014; 123:1709-1719.
33. Nemunaitis J, Fong T, Shabe P, Martineau D, Ando D. Comparison of serum interleukin-10 (il-10) levels between normal volunteers and patients with advanced melanoma. Cancer Invest. 2001; 19:239-247.
34. Deng J, Carlson N, Takeyama K, Dal Cin P, Shipp M, Letai A. Bh3 profiling identifies three distinct classes of apoptotic blocks to predict response to abt-737 and conventional chemotherapeutic agents. Cancer Cell. 2007; 12:171-185.
35. McCarthy A, Marzec J, Clear A, Petty RD, Coutinho R, Matthews J, Wilson A, Iqbal S, Calaminici M, Gribben JG, Jia L. Dysregulation of autophagy in human follicular lymphoma is independent of overexpression of bcl-2. Oncotarget. 2014; 5:11653-11668.
36. Liu FT, Agrawal SG, Gribben JG, Ye H, Du MQ, Newland AC, Jia L. Bortezomib blocks bax degradation in malignant b cells during treatment with trail. Blood. 2008; 111:2797-2805.
37. Zhao T, Ren H, Jia L, Chen J, Xin W, Yan F, Li J, Wang X, Gao S, Qian D, Huang C, Hao J. Inhibition of hif-1alpha by px-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma. Oncotarget. 2015; 6:2250-2262.
38. Romani N, Gruner S, Brang D, Kampgen E, Lenz A, Trockenbacher B, Konwalinka G, Fritsch PO, Steinman RM, Schuler G. Proliferating dendritic cell progenitors in human blood. J Exp Med. 1994; 180:83-93.
39. Reitan NK, Sporsheim B, Bjorkoy A, Strand S, Davies Cde L. Quantitative 3-d colocalization analysis as a tool to study the intracellular trafficking and dissociation of pdna-chitosan polyplexes. J Biomed Opt. 2012; 17:026015.
40. Li Q, Lau A, Morris TJ, Guo L, Fordyce CB, Stanley EF. A syntaxin 1, galpha(o), and n-type calcium channel complex at a presynaptic nerve terminal: Analysis by quantitative immunocolocalization. J Neurosci. 2004; 24:4070-4081.
41. Wang P, Wang P, Liu B, Zhao J, Pang Q, Agrawal SG, Jia L, Liu FT. Dynamin-related protein drp1 is required for bax translocation to mitochondria in response to irradiation-induced apoptosis. Oncotarget 2015.
42. Kepp O, Senovilla L, Kroemer G. Immunogenic cell death inducers as anticancer agents. Oncotarget. 2014; 5:5190-5191.
43. Bachireddy P, Burkhardt UE, Rajasagi M, Wu CJ. Haematological malignancies: At the forefront of immunotherapeutic innovation. Nat Rev Cancer. 2015; 15:201-215.
44. Coutinho R, Clear AJ, Mazzola E, Owen A, Greaves P, Wilson A, Matthews J, Lee A, Alvarez R, Gomes da Silva M, Cabecadas J, Neuberg D, Calaminici M, Gribben JG. Revisiting the immune microenvironment of diffuse large b-cell lymphoma using a tissue microarray and immunohistochemistry: Robust semi-automated analysis reveals cd3 and foxp3 as potential predictors of response to r-chop. Haematologica. 2014; .
45. Jais JP, Haioun C, Molina TJ, Rickman DS, de Reynies A, Berger F, Gisselbrecht C, Briere J, Reyes F, Gaulard P, Feugier P, Labouyrie E, Tilly H, et al. The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large b-cell lymphoma treated with chop and rituximab. Leukemia. 2008; 22:1917-1924.
46. Lee H, Shin N, Song M, Kang UB, Yeom J, Lee C, Ahn YH, Yoo JS, Paik YK, Kim H. Analysis of nuclear high mobility group box 1 (hmgb1)-binding proteins in colon cancer cells: Clustering with proteins involved in secretion and extranuclear function. J Proteome Res. 2010; 9:4661-4670.
47. Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013; 31:51-72.
48. Huang X, Meng B, Iqbal J, Ding BB, Perry AM, Cao W, Smith LM, Bi C, Jiang C, Greiner TC, Weisenburger DD, Rimsza L, Rosenwald A, et al. Activation of the stat3 signaling pathway is associated with poor survival in diffuse large b-cell lymphoma treated with r-chop. J Clin Oncol. 2013; 31:4520-4528.
49. Zhu C, Sakuishi K, Xiao S, Sun Z, Zaghouani S, Gu G, Wang C, Tan DJ, Wu C, Rangachari M, Pertel T, Jin HT, Ahmed R, Anderson AC, Kuchroo VK. An il-27/nfil3 signalling axis drives tim-3 and il-10 expression and t-cell dysfunction. Nat Commun. 2015; 6:6072.
50. Singh J, Dixon GH. High mobility group proteins 1 and 2 function as general class ii transcription factors. Biochemistry. 1990; 29:6295-6302.
51. Brickman JM, Adam M, Ptashne M. Interactions between an hmg-1 protein and members of the rel family. Proc Natl Acad Sci U S A. 1999; 96:10679-10683.
52. Semino C, Angelini G, Poggi A, Rubartelli A. Nk/idc interaction results in il-18 secretion by dcs at the synaptic cleft followed by nk cell activation and release of the dc maturation factor hmgb1. Blood. 2005; 106:609-616.
53. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012; 12:278-287.